NASDAQ:GLPG - GALAPAGOS NV/S Stock Price, Forecast & News

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

13 analysts have issued twelve-month target prices for GALAPAGOS NV/S's shares. Their forecasts range from $130.00 to $302.00. On average, they expect GALAPAGOS NV/S's stock price to reach $212.90 in the next twelve months. This suggests that the stock has a possible downside of 13.3%. View Analyst Price Targets for GALAPAGOS NV/S.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 3 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GALAPAGOS NV/S.

Media coverage about GLPG stock has been trending neutral on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for GALAPAGOS NV/S.

Some companies that are related to GALAPAGOS NV/S include Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN) and Mylan (MYL).

Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), argenx (ARGX), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Pharming Group (PHGUF), Collegium Pharmaceutical (COLL), Trade Desk (TTD), Sociedad Quimica y Minera de Chile (SQM) and Biogen (BIIB).

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

GALAPAGOS NV/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (4.82%), FMR LLC (1.10%), Bessemer Group Inc. (0.49%), Jane Street Group LLC (0.17%), Public Employees Retirement Association of Colorado (0.15%) and Bank of America Corp DE (0.12%).

GLPG stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Eventide Asset Management LLC, Sands Capital Management LLC, Bessemer Group Inc., Bank of America Corp DE, Bank of New York Mellon Corp, FMR LLC and Employees Retirement System of Texas.

GLPG stock was acquired by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, 1832 Asset Management L.P., Acadian Asset Management LLC, Barclays PLC, Jane Street Group LLC, Russell Investments Group Ltd., Geode Capital Management LLC and Goldman Sachs Group Inc..

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GLPG stock can currently be purchased for approximately $245.54.

GALAPAGOS NV/S has a market capitalization of $13.46 billion and generates $375.54 million in revenue each year. The biotechnology company earns $-34,560,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. View Additional Information About GALAPAGOS NV/S.

The official website for GALAPAGOS NV/S is http://www.glpg.com/.

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]